Griffiths, Paul http://orcid.org/0000-0001-9317-5915
Reeves, Matthew http://orcid.org/0000-0002-4909-1076
Article History
Accepted: 18 May 2021
First Online: 24 June 2021
Competing interests
: Both authors are co-inventors (along with I. Baraniak) on UK patent application number 2020135.6 assigned to University College London (UCL), entitled ‘hCMV antibody and vaccine target’, that deals with a novel antigenic domain on HCMV glycoprotein B (gB). UCL received funds from Takeda pharmaceuticals to compensate for the time P.G. spent as a member of the end-point committee for a randomized clinical trial (RCT) of maribavir. The authors declare no other competing interests.
Free to read: This content has been made available to all.